Silencing DUX4 Expression in FSHD Cells by CRISPR

Alec DeSimone  
*University of Massachusetts Medical School*

Peter L. Jones  
*University of Massachusetts Medical School Worcester*

Michael Broadsky  
*University of Massachusetts Medical School*

*See next page for additional authors*

Follow this and additional works at: [https://escholarship.umassmed.edu/cts_retreat](https://escholarship.umassmed.edu/cts_retreat)

Part of the [Cell and Developmental Biology Commons](https://escholarship.umassmed.edu/cell_dev_bio), [Genetics Commons](https://escholarship.umassmed.edu/genetics), [Molecular Genetics Commons](https://escholarship.umassmed.edu/molec_genetics), [Musculoskeletal Diseases Commons](https://escholarship.umassmed.edu/musculoskeletal_diseases), and the [Translational Medical Research Commons](https://escholarship.umassmed.edu/translational_medical)

DeSimone, Alec; Jones, Peter L.; Broadsky, Michael; Wagner, Kathryn; Bibat, Genila; and Emerson, Charles P. Jr., 'Silencing DUX4 Expression in FSHD Cells by CRISPR' (2014). *UMass Center for Clinical and Translational Science Research Retreat*. 35.  
[https://escholarship.umassmed.edu/cts_retreat/2014/posters/35](https://escholarship.umassmed.edu/cts_retreat/2014/posters/35)

This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Center for Clinical and Translational Science Research Retreat by an authorized administrator of eScholarship@UMMS. For more information, please contact Lisa.Palmer@umassmed.edu.
Presenter Information
Alec DeSimone, Peter L. Jones, Michael Broadsky, Kathryn Wagner, Genila Bibat, and Charles P. Emerson Jr.

Comments
Abstract of poster presented at the 2014 UMass Center for Clinical and Translational Science Research Retreat, held on May 20, 2014 at the University of Massachusetts Medical School, Worcester, Mass.

Creative Commons License

This work is licensed under a Creative Commons Attribution-Noncommercial-Share Alike 3.0 License.
Silencing DUX4 Expression in FSHD Cells by CRISPR
Alec DeSimone¹, Peter Jones¹, Michael Broadsky¹, Kathryn Wagner², Genila Bibat², and Charles P Emerson Jr.¹

¹Wellstone Center for FSHD Research, University Of Massachusetts Medical School, Worcester MA
²Center for Genetic Muscle Disorders, Kennedy Krieger Institute, Johns Hopkins School of Medicine, Baltimore, MD

Contact:
Alec M DeSimone PhD,
Lab: 774-455-1574
Alec_DeSimone@umassmed.edu

Facioscapulohumeral Muscular Dystrophy (FSHD) is an autosomal dominant neuromuscular disease affecting 1 in 20,000 to 1 in 15,000 individuals and is characterized by progressive weakness in the facial, scapular, humeral, truncal, and lower extremity muscles (Tawil and Van Der Maarel Muscle Nerve 2006). FSHD is associated with the contraction of the D4Z4 microsatellite repeat below a threshold number of repeats (Wijmenga et al., Nat. Genet, 1992), allowing the transcription of the DUX4 gene contained within the last repeat (Snider et al., PLoS Gen, 2010). The disease only develops when DUX4 is expressed from a chromosome with the permissive 4qA allele, which contains a polyadenylation signal (PAS) that stabilizes the DUX4 transcript (Lemmers et al., Science, 2010). We are using CRISPR technology to investigate the possibility that disruption of the PAS in cells derived from FSHD patients could prevent expression of the DUX4 protein and restore the cell to a less affected phenotype. We will then take advantage of the high reprogramming efficiency of FSHD cells and generate iPSC from FSHD muscle cells with the repressed DUX4 allele, and determine if they have a similar phenotype to iPS cells derived from non-affected individuals. Finally, we will use the highly-engraftable iPS cells in xenograft experiments to determine if the DUX4-silenced iPSCs repopulate injured muscle more efficiently than unaltered FSHD-derived iPSC, and evaluate their potential for use as therapeutics.